Alpha 2.0
Login Register
» Authors » Caroline Mollevi

Caroline Mollevi

Explore the profile of Caroline Mollevi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 62
Citations 1226
Followers 0
Related Specialties
Oncology
General Medicine
Molecular Biology
Top 10 Co-Authors
William Jacot
Florence Boissiere-Michot
Severine Guiu
Evelyne Lopez-Crapez
Marc Ychou
Sophie Gourgou
Joelle Simony-Lafontaine
Eric Assenat
Celine Gongora
Celia Touraine
Published In
Cancers (Basel)
Int J Cancer
Front Endocrinol (Lausanne)
BMC Cancer
Br J Cancer
Affiliations
Soon will be listed here.
Recent Articles
11.
When a joint model should be preferred over a linear mixed model for analysis of longitudinal health-related quality of life data in cancer clinical trials
Touraine C, Cuer B, Conroy T, Juzyna B, Gourgou S, Mollevi C
BMC Med Res Methodol . 2023 Feb; 23(1):36. PMID: 36765307
Background: Patient-reported outcomes such as health-related quality of life (HRQoL) are increasingly used as endpoints in randomized cancer clinical trials. However, the patients often drop out so that observation of...
12.
Individualized luteal phase support based on serum progesterone levels in frozen-thawed embryo transfer cycles maximizes reproductive outcomes in a cohort undergoing preimplantation genetic testing
du Boulet B, Ranisavljevic N, Mollevi C, Bringer-Deutsch S, Brouillet S, Anahory T
Front Endocrinol (Lausanne) . 2022 Dec; 13:1051857. PMID: 36531476
Introduction: Low serum progesterone concentration on frozen embryo transfer (FET) day in hormone replacement therapy (HRT) cycles results in lower reproductive outcomes. Recent studies showed the efficiency of a "rescue...
13.
"Short agonist stop" protocol, an ovarian stimulation for poor responders in fertilization (IVF): A pilot study
Mauries C, Ranisavljevic N, Mollevi C, Brunet C, Hamamah S, Brouillet S, et al.
Front Endocrinol (Lausanne) . 2022 Dec; 13:1056520. PMID: 36465628
Introduction: Poor responder patients remain a challenge in assisted reproductive technologies. The "short agonist stop" (SAS) stimulation protocol uses a double stimulation (flare up effect with the gonadotropin-releasing hormone (GnRH)...
14.
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity
Alcaraz L, Mallavialle A, Mollevi C, Boissiere-Michot F, Mansouri H, Simony-Lafontaine J, et al.
Int J Cancer . 2022 Nov; 152(6):1243-1258. PMID: 36346290
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and lacks specific targeted therapeutic agents. The current mechanistic evidence from cell-based studies suggests that the matricellular protein SPARC...
15.
Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer
Bobrie A, Massol O, Ramos J, Mollevi C, Lopez-Crapez E, Bonnefoy N, et al.
Cancers (Basel) . 2022 Oct; 14(19). PMID: 36230752
Background: Triple-negative breast cancers (TNBCs) have a worse prognosis, but might respond to immunotherapies. Macrophages are plastic cells that can adopt various phenotypes and functions. Although they are a major...
16.
Cross-sectional nationwide mixed-methods population-based study of living conditions, and identification of sexual and fertility profiles among young women after breast cancer in France: the Candy study protocol
Assogba E, Dumas A, Woronoff A, Mollevi C, Coutant C, Ladoire S, et al.
BMJ Open . 2022 Sep; 12(9):e056834. PMID: 36171047
Introduction: At the end of the treatment, many young breast cancer (BC) survivors face difficulties related to fertility and sexuality, mainly due to the side effects of treatment. Integrating patient...
17.
Flexible modeling of longitudinal health-related quality of life data accounting for informative dropout in a cancer clinical trial
Winter A, Cuer B, Conroy T, Juzyna B, Gourgou S, Mollevi C, et al.
Qual Life Res . 2022 Sep; 32(3):669-679. PMID: 36115002
Purpose: A joint modeling approach is recommended for analysis of longitudinal health-related quality of life (HRQoL) data in the presence of potentially informative dropouts. However, the linear mixed model modeling...
18.
EBBE-Text: Explaining Neural Networks by Exploring Text Classification Decision Boundaries
Delaforge A, Aze J, Bringay S, Mollevi C, Sallaberry A, Servajean M
IEEE Trans Vis Comput Graph . 2022 Jun; 29(10):4154-4171. PMID: 35724275
While neural networks (NN) have been successfully applied to many NLP tasks, the way they function is often difficult to interpret. In this article, we focus on binary text classification...
19.
hybridization for the assessment of urokinase plasminogen activator and plasminogen activator inhibitor type‑1 in formalin‑fixed paraffin‑embedded breast cancer specimens
Boissiere-Michot F, Mollevi C, Baecker V, Crapez E, Jacot W
Int J Mol Med . 2022 Apr; 49(6). PMID: 35475537
Urokinase plasminogen activator (uPA) and its inhibitor, plasminogen activator inhibitor type 1 (PAI‑1), have been reported as prognostic and predictive biomarkers in breast cancer, particularly in patients with node‑negative tumors....
20.
Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects
Leenhardt F, Fiteni F, Gauthier L, Alexandre M, Guiu S, Firmin N, et al.
Pharmaceutics . 2022 Apr; 14(4). PMID: 35456675
Palbociclib is a good candidate for therapeutic drug monitoring (TDM) due to its narrow therapeutic range and frequency of toxicities, particularly high-grade neutropenia. In this prospective, bicentric clinical trial, we...